The search for disease modification in moderate to severe Alzheimer disease : A critical review of current evidenceFARLOW, Martin R.Neurology. 2005, Vol 65, Num 6, pp S25-S30, issn 0028-3878, SUP3Article

Progress in understanding moderate to severe Alzheimer diseaseFARLOW, Martin R.Neurology. 2005, Vol 65, Num 6, issn 0028-3878, 35 p., SUP3Serial Issue

Use of antidementia agents in vascular dementia : Beyond Alzheimer diseaseFARLOW, Martin R.Mayo Clinic proceedings. 2006, Vol 81, Num 10, pp 1350-1358, issn 0025-6196, 9 p.Article

Clinical pharmacokinetics of galantamineFARLOW, Martin R.Clinical pharmacokinetics. 2003, Vol 42, Num 15, pp 1383-1392, issn 0312-5963, 10 p.Article

Cost consequences and cost benefits of treating patients with moderate to severe Alzheimer diseaseFILLIT, Howard.Neurology. 2005, Vol 65, Num 6, pp S31-S33, issn 0028-3878, SUP3Article

A Modern Hypothesis : The Distinct Pathologies of Dementia Associated with Parkinson's Disease versus Alzheimer's DiseaseFARLOW, Martin R; CUMMINGS, Jeffrey.Dementia and geriatric cognitive disorders. 2008, Vol 25, Num 4, pp 301-308, issn 1420-8008, 8 p.Article

Memantine for the Treatment of Alzheimer's Disease : Tolerability and Safety Data from Clinical TrialsFARLOW, Martin R; GRAHAM, Stephen M; ALVA, Gustavo et al.Drug safety. 2008, Vol 31, Num 7, pp 577-585, issn 0114-5916, 9 p.Article

Neuroanatomy/pathology and the interplay of neurotransmitters in moderate to severe Alzheimer diseaseFRANCIS, Paul T.Neurology. 2005, Vol 65, Num 6, pp S5-S9, issn 0028-3878, SUP3Article

The staging and assessment of moderate to severe Alzheimer diseaseFELDMAN, H. H; WOODWARD, M.Neurology. 2005, Vol 65, Num 6, pp S10-S17, issn 0028-3878, SUP3Article

Neuropsychiatric and behavioral alterations and their management in moderate to severe Alzheimer diseaseCUMMINGS, Jeffrey L.Neurology. 2005, Vol 65, Num 6, pp S18-S24, issn 0028-3878, SUP3Article

Treatment Options in Alzheimer's Disease : Maximizing Benefit, Managing ExpectationsFARLOW, Martin R; MILLER, Michael L; PEJOVIC, Vojislav et al.Dementia and geriatric cognitive disorders. 2008, Vol 25, Num 5, pp 408-422, issn 1420-8008, 15 p.Article

Effective pharmacologic management of Alzheimer's diseaseFARLOW, Martin R; CUMMINGS, Jeffrey L.The American journal of medicine. 2007, Vol 120, Num 5, pp 388-397, issn 0002-9343, 10 p.Article

Pharmacokinetic profiles of current therapies for alzheimer's disease: Implications for switching to galantamineFARLOW, Martin R.Clinical therapeutics. 2001, Vol 23, pp A13-A24, issn 0149-2918, SUPAArticle

Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression : Results of a meta-analysisFARLOW, Martin R; SMALL, Garv W; QUARA, Peter et al.Dementia and geriatric cognitive disorders. 2005, Vol 20, Num 2-3, pp 192-197, issn 1420-8008, 6 p.Article

Results, Rhetoric, and Randomized Trials : The Case of Donepezil. Editorial commentGILSTAD, John R; FINUCANE, Thomas E; FARLOW, Martin R et al.Journal of the American Geriatrics Society. 2008, Vol 56, Num 8, issn 0002-8614, 1556-1562, 1566-1567 [9 p.]Article

Effects of Rivastigmine Transdermal Patch and Capsule on Aspects of Clinical Global Impression of Change in Alzheimer's Disease: A Retrospective AnalysisCUMMINGS, Jeffrey L; FERRIS, Steven H; FARLOW, Martin R et al.Dementia and geriatric cognitive disorders. 2010, Vol 29, Num 5, pp 406-412, issn 1420-8008, 7 p.Article

A 24-Week, Randomized, Controlled Trial of Rivastigmine Patch 13.3 mg/24 h Versus 4.6 mg/24 h in Severe Alzheimer's DementiaFARLOW, Martin R; GROSSBERG, George T; SADOWSKY, Carl H et al.CNS neuroscience & therapeutics (Print). 2013, Vol 19, Num 10, pp 745-752, issn 1755-5930, 8 p.Article

Efficacy of Rivastigmine on Executive Function in Patients with Parkinson's Disease DementiaSCHMITT, Frederick A; FARLOW, Martin R; XIANGYI MENG et al.CNS neuroscience & therapeutics (Print). 2010, Vol 16, Num 6, pp 330-336, issn 1755-5930, 7 p.Article

Current drug targets for Alzheimer's disease treatmentLAHIRI, Debomoy K; FARLOW, Martin R; GREIG, Nigel H et al.Drug development research. 2002, Vol 56, Num 3, pp 267-281, issn 0272-4391, 15 p.Article

Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progressionFARLOW, Martin R; HAKE, Ann; MESSINA, John et al.Archives of neurology (Chicago). 2001, Vol 58, Num 3, pp 417-422, issn 0003-9942Article

Medication for Alzheimer's Disease and Associated Fall Hazard: A Retrospective Cohort Study from the Alzheimer's Disease Neuroimaging InitiativeEPSTEIN, Noam U; RONG GUO; FARLOW, Martin R et al.Drugs & aging. 2014, Vol 31, Num 2, pp 125-129, issn 1170-229X, 5 p.Article

Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapyFARLOW, Martin R; GROSSBERG, George T; XIANGYI MENG et al.International journal of geriatric psychiatry. 2011, Vol 26, Num 12, pp 1236-1243, issn 0885-6230, 8 p.Article

Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAP kinase in rat cerebellar granule neuronsSUIZHEN LIN; YUQIN ZHANG; DODEL, Richard et al.Neuroscience letters. 2001, Vol 315, Num 1-2, pp 61-64, issn 0304-3940Article

Temporoparietal Hypometabolism in Frontotemporal Lobar Degeneration and Associated Imaging Diagnostic ErrorsWOMACK, Kyle B; DIAZ-ARRASTIA, Ramon; PESKIND, Elaine R et al.Archives of neurology (Chicago). 2011, Vol 68, Num 3, pp 329-337, issn 0003-9942, 9 p.Article

Correlation of Clinical Features With Argyrophilic Grains at AutopsySABBAGH, Marwan N; SANDHU, Sonny S; FARLOW, Martin R et al.Alzheimer disease and associated disorders. 2009, Vol 23, Num 3, pp 229-233, issn 0893-0341, 5 p.Article